Results 1 to 10 of about 948,328 (207)

Generation of a humanized Aβ expressing mouse demonstrating aspects of Alzheimer’s disease-like pathology

Nature Communications, 2021
Most instances of Alzheimer’s disease (AD) are sporadic or not associated with a particular mutation. Here, the authors develop knock-in mice that express wildtype human Aβ under control of the mouse App locus, which may have potential for modelling some
David Baglietto-Vargas, Stefania Forner, Lena Cai, Alessandra C. Martini, Laura Trujillo-Estrada, Vivek Swarup, Marie Minh Thu Nguyen, Kelly Do Huynh, Dominic I. Javonillo, Kristine Minh Tran, Jimmy Phan, Shan Jiang, Enikö A. Kramár, Cristina Nuñez-Diaz, Gabriela Balderrama-Gutierrez, Franklin Garcia, Jessica Childs, Carlos J. Rodriguez-Ortiz, Juan Antonio Garcia-Leon, Masashi Kitazawa, Mohammad Shahnawaz, Dina P. Matheos, Xinyi Ma, Celia Da Cunha, Ken C. Walls, Rahasson R. Ager, Claudio Soto, Antonia Gutierrez, Ines Moreno-Gonzalez, Ali Mortazavi, Andrea J. Tenner, Grant R. MacGregor, Marcelo Wood, Kim N. Green, Frank M. LaFerla   +34 more
doaj   +1 more source

Reasons for undergoing amyloid imaging among cognitively unimpaired older adults

Annals of Clinical and Translational Neurology, 2021
Objectives Preclinical Alzheimer’s disease (AD) clinical trials screen cognitively unimpaired older adults for biomarker criteria and disclose their results.
Mary M. Ryan, Daniel L. Gillen, Joshua D. Grill   +2 more
doaj   +1 more source

Recruitment across two decades of NIH-funded Alzheimer’s disease clinical trials

Alzheimer’s Research & Therapy, 2023
Background Timely accrual of a representative sample is a key factor in whether Alzheimer’s disease (AD) clinical trials successfully answer the scientific questions under study.
Marina Ritchie, Daniel L. Gillen, Joshua D. Grill   +2 more
doaj   +1 more source

Estimating attrition in mild-to-moderate Alzheimer’s disease and mild cognitive impairment clinical trials

Alzheimer’s Research & Therapy, 2023
Background Participant retention is a key factor that affects clinical trial integrity. Trial protocols estimate attrition as a function of sample size calculations. Alzheimer’s disease (AD) is an area of active treatment development.
Marina Ritchie, Daniel L. Gillen, Joshua D. Grill   +2 more
doaj   +1 more source

Microglial APOE4: more is less and less is more

Molecular Neurodegeneration, 2023
Apolipoprotein E (APOE) is the single greatest genetic risk factor for late onset Alzheimer’s disease (AD). Yet, the cell-specific effects of APOE on microglia function have remained unclear.
Ghazaleh Eskandari-Sedighi, Mathew Blurton-Jones   +1 more
doaj   +1 more source

IL-1β suppresses cLTP-induced surface expression of GluA1 and actin polymerization via ceramide-mediated Src activation

Journal of Neuroinflammation, 2018
Background Brain inflammation including increases in inflammatory cytokines such as IL-1β is widely believed to contribute to the pathophysiology of Alzheimer’s disease.
Liqi Tong, G. Aleph Prieto, Carl W. Cotman   +2 more
doaj   +1 more source

Study partner types and prediction of cognitive performance: implications to preclinical Alzheimer’s trials

Alzheimer’s Research & Therapy, 2019
Background Alzheimer’s disease (AD) clinical trials require enrollment of a participant and a study partner, whose role includes assessing participant cognitive and functional performance.
Michelle M. Nuño, Daniel L. Gillen, Joshua D. Grill, for the Alzheimer’s Disease Cooperative Study   +3 more
doaj   +1 more source

Blood pressure variability and plasma Alzheimer’s disease biomarkers in older adults

Scientific Reports, 2022
Blood pressure variability is an emerging risk factor for Alzheimer’s disease in older adults, independent of average blood pressure levels. Growing evidence suggests increased blood pressure variability is linked to Alzheimer’s disease pathophysiology ...
Isabel J. Sible, Belinda Yew, Jung Yun Jang, John Paul M. Alitin, Yanrong Li, Aimée Gaubert, Amy Nguyen, Shubir Dutt, Anna E. Blanken, Jean K. Ho, Anisa J. Marshall, Arunima Kapoor, Fatemah Shenasa, Kathleen E. Rodgers, Virginia E. Sturm, Elizabeth Head, Alessandra Martini, Daniel A. Nation   +17 more
doaj   +1 more source

Reactions to learning a “not elevated” amyloid PET result in a preclinical Alzheimer’s disease trial

Alzheimer’s Research & Therapy, 2018
Background The experiences of biomarker-ineligible cognitively normal persons can inform trial conduct and the translation of preclinical Alzheimer’s disease (AD) into clinical practice.
Joshua D. Grill, Chelsea G. Cox, Kristin Harkins, Jason Karlawish   +3 more
doaj   +1 more source

SENSory re-learning of the UPPer limb (SENSUPP) after stroke: development and description of a novel intervention using the TIDieR checklist

Trials, 2021
Background Sensorimotor impairments of upper limb (UL) are common after stroke, leading to difficulty to use the UL in daily life. Even though many have sensory impairments in the UL, specific sensory training is often lacking in stroke rehabilitation ...
Håkan Carlsson, Birgitta Rosén, Anders Björkman, Hélène Pessah-Rasmussen, Christina Brogårdh   +4 more
doaj   +1 more source